68 patients did not experience discontinuation of the drug due to serious adverse events or treatment-related related deaths, thus showing the safety of the two methods in treating patients with advanced NSCLC with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.